|Day's Range||34.94 - 35.25|
|52 Week Range||25.55 - 35.60|
|PE Ratio (TTM)||26.27|
|Dividend & Yield||1.90 (5.42%)|
|1y Target Est||N/A|
The agenda was dominated by eurozone economic data, the anniversary of Britain's vote to leave the EU and a political summit in Brussels on Friday.
Tesaro's Zejula would likely outperform drugs from Clovis and AstraZeneca in immuno-oncology combinations with Merck, Bristol or Roche.
Regeneron (REGN) and Sanofi (SNY) are exploring the use of Dupixent in other indications such as asthma, pediatric AD, nasal polyps, and eosinophilic esophagitis.